Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?

Simply Wall St.08-16

In the past quarter, Krystal Biotech, Inc. reported Q2 2026 net income of US$54.77 million, with basic earnings per share from continuing operations of US$1.85, up from US$38.33 million and US$1.33 a ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2659817185?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-08-16 09:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659817185","market":"sg","top_or_hot":-1,"title":"Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?","media":"Simply Wall St.","content":"<div>\n<p>In the past quarter, Krystal Biotech, Inc. reported Q2 2026 net income of US$54.77 million, with basic earnings per share from continuing operations of US$1.85, up from US$38.33 million and US$1.33 a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/should-surging-vyjuvek-driven-earnings-reshape-how-krystal-b\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-16 09:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/should-surging-vyjuvek-driven-earnings-reshape-how-krystal-b><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the past quarter, Krystal Biotech, Inc. reported Q2 2026 net income of US$54.77 million, with basic earnings per share from continuing operations of US$1.85, up from US$38.33 million and US$1.33 a ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/should-surging-vyjuvek-driven-earnings-reshape-how-krystal-b\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XBI","symbol_name":"SPDR S&P Biotech ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/should-surging-vyjuvek-driven-earnings-reshape-how-krystal-b","article_id":"2659817185","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-krys/krystal-biotech/news/should-surging-vyjuvek-driven-earnings-reshape-how-krystal-b","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2659817185","pubTimestamp":1786843346,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In the past quarter, Krystal Biotech, Inc. reported Q2 2026 net income of US$54.77 million, with basic earnings per share from continuing operations of US$1.85, up from US$38.33 million and US$1.33 a year earlier.\nOver the first half of 2026, net income rose to US$110.70 million and higher per-share earnings underscored the earnings power of Vyjuvek alongside an advancing gene therapy pipeline.\nWe’ll now examine how this stronger profitability profile, anchored by Vyjuvek’s contribution,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"XBI":"SPDR S&P Biotech ETF","KRYS":"Krystal Biotech Inc.","ISBC":"投资者银行"},"translate_title":"Vyjuvek 推动的盈利飙升是否会重塑 Krystal Biotech (KRYS) 投资者对其风险状况的看法？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1.5,"ISBC":1.5,"KRYS":1.5},"content_text":"In the past quarter, Krystal Biotech, Inc. reported Q2 2026 net income of US$54.77 million, with basic earnings per share from continuing operations of US$1.85, up from US$38.33 million and US$1.33 a year earlier. Over the first half of 2026, net income rose to US$110.70 million and higher per-share earnings underscored the earnings power of Vyjuvek alongside an advancing gene therapy pipeline. We’ll now examine how this stronger profitability profile, anchored by Vyjuvek’s contribution, reshapes Krystal Biotech’s existing investment narrative and risk balance. Outshine the giants: these 17 early-stage AI stocks could fund your retirement.AdvertisementKrystal Biotech Investment Narrative RecapTo own Krystal Biotech, you need to believe Vyjuvek can support durable profitability while the broader gene therapy pipeline matures. The latest Q2 2026 results highlight stronger earnings, but they do not materially change the core near term catalyst, which remains execution on Vyjuvek’s global rollout. The biggest risk still centers on revenue volatility and margin pressure if patient treatment patterns, pricing, or reimbursement for Vyjuvek become less favorable than the recent profit trajectory suggests. The recent UK marketing authorization for Vyjuvek is especially relevant alongside these earnings, because it reinforces how much of Krystal’s story now rests on successful international expansion. UK approval, with orphan designation and potential long market exclusivity, supports near term revenue opportunities but also sharpens focus on reimbursement decisions, pricing discussions, and the cost of reaching more dispersed DEB patients, all of which tie directly back into the risk of fluctuating margins and earnings. Yet behind the stronger earnings, there is a less visible risk around how unpredictable Vyjuvek treatment pauses could affect the stability of returns that investors should be aware of... Read the full narrative on Krystal Biotech (it's free!)Krystal Biotech's narrative projects $1.0 billion revenue and $552.3 million earnings by 2029.Uncover how Krystal Biotech's forecasts yield a $361.67 fair value, a 9% upside to its current price.Exploring Other PerspectivesKRYS 1-Year Stock Price Chart While recent profits look strong, the most cautious analysts were already assuming only about US$793.3 million of revenue and US$288.5 million of earnings by 2029, which shows how differently you might view today’s Vyjuvek driven results compared with concerns about rising costs and unpredictable treatment patterns.Explore 5 other fair value estimates on Krystal Biotech - why the stock might be worth 15% less than the current price!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Krystal Biotech research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Krystal Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Krystal Biotech's overall financial health at a glance.Contemplating Other Strategies?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Krystal Biotech might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2659817185","isCrawlerRequest":true}